CU23904B1 - - Google Patents
Info
- Publication number
- CU23904B1 CU23904B1 CU20100200A CU20100200A CU23904B1 CU 23904 B1 CU23904 B1 CU 23904B1 CU 20100200 A CU20100200 A CU 20100200A CU 20100200 A CU20100200 A CU 20100200A CU 23904 B1 CU23904 B1 CU 23904B1
- Authority
- CU
- Cuba
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4488608P | 2008-04-14 | 2008-04-14 | |
| US15977809P | 2009-03-12 | 2009-03-12 | |
| PCT/US2009/040538 WO2009129246A2 (en) | 2008-04-14 | 2009-04-14 | Compositions and methods for preparing and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20100200A7 CU20100200A7 (es) | 2011-11-15 |
| CU23904B1 true CU23904B1 (es) | 2013-06-28 |
Family
ID=41199689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2010000200A CU20100200A7 (es) | 2008-04-14 | 2010-10-13 | Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8808742B2 (es) |
| EP (1) | EP2291350A4 (es) |
| JP (1) | JP2011518786A (es) |
| KR (1) | KR20110014149A (es) |
| CN (1) | CN102131771A (es) |
| AU (1) | AU2009236325A1 (es) |
| BR (1) | BRPI0911297A2 (es) |
| CA (1) | CA2720671A1 (es) |
| CO (1) | CO6331425A2 (es) |
| CR (1) | CR11731A (es) |
| CU (1) | CU20100200A7 (es) |
| DO (1) | DOP2010000304A (es) |
| EA (1) | EA201001639A1 (es) |
| EC (1) | ECSP10010548A (es) |
| IL (1) | IL208284A0 (es) |
| MA (1) | MA32226B1 (es) |
| MX (1) | MX2010011314A (es) |
| SG (1) | SG189784A1 (es) |
| WO (1) | WO2009129246A2 (es) |
| ZA (1) | ZA201006944B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| TWI524890B (zh) * | 2009-07-24 | 2016-03-11 | 亞德生化公司 | （ｒ）－ｎ－（３，４－二氟－２－（２－氟－４－碘苯胺基）－６－甲氧基苯基）－１－（２，３－二羥丙基）環丙烷－１－磺醯胺及（ｓ）－ｎ－（３，４－二氟－２－（２－氟－４－碘苯胺基）－６－甲氧基苯基）－１－（２，３－二羥丙基）環丙烷－１－磺醯胺之製備 |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| CA2814617C (en) * | 2009-10-13 | 2017-12-19 | Allostem Therapeutics Llc | Novel mek inhibitors, useful in the treatment of diseases |
| EA201201414A8 (ru) * | 2010-04-16 | 2013-12-30 | Байер Интеллектчуал Проперти Гмбх | КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| CN103570594A (zh) * | 2012-08-01 | 2014-02-12 | 苏州迈泰生物技术有限公司 | 二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途 |
| WO2014071183A1 (en) | 2012-11-02 | 2014-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| EP2848246A1 (en) | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| EP3043778B1 (en) * | 2013-09-13 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| EP3187491A4 (en) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| US11096987B2 (en) | 2015-08-28 | 2021-08-24 | Bioincept, Llc | Mutant peptides and methods of treating subjects using the same |
| WO2017040186A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Compositions and methods for the treatment of neurodamage |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| DK3609464T3 (da) * | 2017-04-13 | 2021-08-30 | Jean Paul Remon | Xanthohumolbaserede sammensætninger |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CN113476476A (zh) * | 2021-08-25 | 2021-10-08 | 娜布其 | 一种治疗白癜风疾病的药物及其制作工艺 |
| EP4788839A1 (en) | 2023-10-03 | 2026-08-12 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8005A (en) * | 1851-04-01 | He ne y bo o t | ||
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| JP2002534515A (ja) * | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | １−複素環置換されたジアリールアミン |
| US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| MX2008002114A (es) * | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| US7842836B2 (en) | 2006-04-11 | 2010-11-30 | Ardea Biosciences | N-aryl-N'alkyl sulfamides as MEK inhibitors |
| CA2694646C (en) * | 2007-07-30 | 2017-09-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| CN103479604B (zh) * | 2007-07-30 | 2016-08-10 | 阿迪生物科学公司 | 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法 |
| US8044240B2 (en) * | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
-
2009
- 2009-04-14 CN CN2009801180672A patent/CN102131771A/zh active Pending
- 2009-04-14 SG SG2013028378A patent/SG189784A1/en unknown
- 2009-04-14 KR KR1020107025394A patent/KR20110014149A/ko not_active Withdrawn
- 2009-04-14 JP JP2011505138A patent/JP2011518786A/ja active Pending
- 2009-04-14 EP EP09732683A patent/EP2291350A4/en not_active Withdrawn
- 2009-04-14 US US12/937,630 patent/US8808742B2/en not_active Expired - Fee Related
- 2009-04-14 MX MX2010011314A patent/MX2010011314A/es active IP Right Grant
- 2009-04-14 CA CA2720671A patent/CA2720671A1/en not_active Abandoned
- 2009-04-14 EA EA201001639A patent/EA201001639A1/ru unknown
- 2009-04-14 WO PCT/US2009/040538 patent/WO2009129246A2/en not_active Ceased
- 2009-04-14 AU AU2009236325A patent/AU2009236325A1/en not_active Abandoned
- 2009-04-14 BR BRPI0911297A patent/BRPI0911297A2/pt not_active IP Right Cessation
-
2010
- 2010-09-21 IL IL208284A patent/IL208284A0/en unknown
- 2010-09-29 ZA ZA2010/06944A patent/ZA201006944B/en unknown
- 2010-10-13 CU CU2010000200A patent/CU20100200A7/es active IP Right Grant
- 2010-10-14 DO DO2010000304A patent/DOP2010000304A/es unknown
- 2010-10-14 CO CO10128068A patent/CO6331425A2/es not_active Application Discontinuation
- 2010-10-14 CR CR11731A patent/CR11731A/es not_active Application Discontinuation
- 2010-10-14 MA MA33245A patent/MA32226B1/fr unknown
- 2010-10-14 EC EC2010010548A patent/ECSP10010548A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011518786A (ja) | 2011-06-30 |
| CR11731A (es) | 2011-06-08 |
| US8808742B2 (en) | 2014-08-19 |
| MX2010011314A (es) | 2010-11-12 |
| AU2009236325A1 (en) | 2009-10-22 |
| DOP2010000304A (es) | 2011-10-15 |
| WO2009129246A3 (en) | 2011-03-31 |
| MA32226B1 (fr) | 2011-04-01 |
| EP2291350A2 (en) | 2011-03-09 |
| CO6331425A2 (es) | 2011-10-20 |
| EA201001639A1 (ru) | 2011-06-30 |
| WO2009129246A2 (en) | 2009-10-22 |
| CA2720671A1 (en) | 2009-10-22 |
| EP2291350A4 (en) | 2012-09-19 |
| BRPI0911297A2 (pt) | 2019-09-24 |
| SG189784A1 (en) | 2013-05-31 |
| CN102131771A (zh) | 2011-07-20 |
| ZA201006944B (en) | 2015-06-24 |
| KR20110014149A (ko) | 2011-02-10 |
| CU20100200A7 (es) | 2011-11-15 |
| ECSP10010548A (es) | 2010-11-30 |
| IL208284A0 (en) | 2010-12-30 |
| US20110033539A1 (en) | 2011-02-10 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |